Conduit Pharmaceuticals has announced a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of common stock with an aggregate offering price of up to $3,556,586. The sales may occur from time to time through A.G.P., acting as the sales agent or principal. Conduit Pharmaceuticals, an emerging growth company listed under the symbol 'CDT' on the Nasdaq Global Market, plans to use the initial proceeds to repay approximately $600,000 in principal from a Bridge Loan Agreement with A.G.P. The company's common stock last traded at $0.091 per share as of October 31, 2024. This move is part of Conduit Pharmaceuticals' efforts to raise capital for working capital and general corporate purposes, including the development of their clinical assets targeting a range of autoimmune disorders.

Conduit Pharmaceuticals has announced a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of common stock with an aggregate offering price of up to $3,556,586. The sales may occur from time to time through A.G.P., acting as the sales agent or principal. Conduit Pharmaceuticals, an emerging growth company listed under the symbol 'CDT' on the Nasdaq Global Market, plans to use the initial proceeds to repay approximately $600,000 in principal from a Bridge Loan Agreement with A.G.P. The company's common stock last traded at $0.091 per share as of October 31, 2024. This move is part of Conduit Pharmaceuticals' efforts to raise capital for working capital and general corporate purposes, including the development of their clinical assets targeting a range of autoimmune disorders.